B-Cell Depletion Cuts Chronic Graft-Versus-Host Disease Risk by 62%
A randomized trial shows prophylactic obinutuzumab dramatically reduces steroid-requiring cGVHD after bone marrow transplant.
Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
264 articles
A randomized trial shows prophylactic obinutuzumab dramatically reduces steroid-requiring cGVHD after bone marrow transplant.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions — from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
Go beyond inflammaging basics to understand how aging reshapes immune cell populations, triggers the SASP, and locks the body into a state of chronic low-grade inflammation at the molecular level.
Scientists reveal how a measles antiviral also blocks Nipah virus and use structural insights to engineer more potent next-generation inhibitors.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
Early influenza infections leave a lasting immunological imprint that determines how your immune system responds to entirely different flu strains later in life.
Virtual patient replicas built from multimodal data may slash trial costs, generate synthetic control arms, and predict treatment response in IBD.
Senescent T cells fuel psoriasis, eczema, and rosacea through toxic secretions. New therapies may finally break the cycle.
A new in vitro study shows Thymosin α1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
A clinical case from Japan illustrates how cryoglobulinemia can drive membranoproliferative glomerulonephritis, a serious kidney complication.
A 2025 meta-analysis of 11 RCTs finds Tα1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
A major review maps emerging immunotherapies—from JAK inhibitors to microbiome interventions—that could transform care for celiac and food allergy patients.